Poolbeg Pharma Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Jeremy Skillington

Algemeen directeur

UK£362.0k

Totale compensatie

Percentage CEO-salaris	69.1%
Dienstverband CEO	3.3yrs
Eigendom CEO	0.2%
Management gemiddelde ambtstermijn	less than a year
Gemiddelde ambtstermijn bestuur	3.3yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Jeremy Skillington's beloning veranderd ten opzichte van Poolbeg Pharma's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-UK£4m
Mar 31 2024	n/a	n/a	-UK£4m
Dec 31 2023	UK£362k	UK£250k	-UK£4m
Sep 30 2023	n/a	n/a	-UK£4m
Jun 30 2023	n/a	n/a	-UK£5m
Mar 31 2023	n/a	n/a	-UK£5m
Dec 31 2022	UK£310k	UK£250k	-UK£5m
Dec 31 2021	UK£261k	n/a	-UK£3m

Compensatie versus markt: De totale vergoeding ($USD 454.60K ) Jeremy } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 474.54K ).

Compensatie versus inkomsten: De vergoeding van Jeremy is gestegen terwijl het bedrijf verliesgevend is.

CEO

Jeremy Skillington (53 yo)

3.3yrs

Tenure

UK£362,000

Compensatie

Dr. Jeremy Skillington, Ph D., serves as Chief Executive Officer and since July 19, 2021 as Director at Poolbeg Pharma PLC. He is Vice President of Business Development at Inflazome Ltd.Dr. Skillington se...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Cathal Friel	Executive Chairman of The Board	3.7yrs	UK£150.00k	4.36% € 1.9m
Jeremy Skillington	CEO & Director	no data	UK£362.00k	0.17% € 75.9k
Ian O'Connell	CFO & Director	no data	UK£237.00k	1.67% € 723.6k
Carol Dalton	Vice President of Investor Relations & Public Relations	1.8yrs	geen gegevens	geen gegevens
John McEvoy	Senior Vice President & Chief Legal Officer	less than a year	geen gegevens	geen gegevens
David Allmond	Chief Business Officer	less than a year	geen gegevens	geen gegevens
Ross Crockett	Group Financial Controller	no data	geen gegevens	geen gegevens

0.9yrs

Gemiddelde duur

53.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 7JN wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.9 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Cathal Friel	Executive Chairman of The Board	3.7yrs	UK£150.00k	4.36% € 1.9m
Jeremy Skillington	CEO & Director	3.3yrs	UK£362.00k	0.17% € 75.9k
Ian O'Connell	CFO & Director	3.5yrs	UK£237.00k	1.67% € 723.6k
Luke O'Neill	Independent Non-Executive Director & Member of Scientific Advisory Board	3.3yrs	UK£40.00k	geen gegevens
Brendan Buckley	Member of Scientific Advisory Board & Independent Non Executive Director	1.9yrs	UK£24.00k	0.53% € 228.7k
Elaine Sullivan	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Edward Gibson	Senior Independent Director	3.3yrs	UK£35.00k	geen gegevens
Daniel Hoft	Member of Scientific Advisory Board	3yrs	geen gegevens	geen gegevens

3.3yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 7JN wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).

Poolbeg Pharma Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Poolbeg Pharma PLC, Annual General Meeting, Jun 13, 2024

Executive Chairman of The Board recently bought €113k worth of stock

Poolbeg Pharma plc Appoints Cathal Friel as Executive Chairman

High number of new and inexperienced directors

Poolbeg Pharma plc Announces Directorate Changes

Poolbeg Pharma plc Announces Executive Appointments

Recent updates

Poolbeg Pharma plc Announces U.S. Patent Office Grants U.S. Immunomodulator I Patent

Poolbeg Pharma Announces Voluntary Delist from OTCQB Market

Poolbeg Pharma PLC, Annual General Meeting, Jun 13, 2024

Poolbeg Pharma PLC Receives the Fully Granted Patent from the U.S. Patent Office for Its Immunomodulator II Patent Application

New minor risk - Financial data availability

Executive Chairman of The Board recently bought €113k worth of stock

Poolbeg Pharma plc Appoints Cathal Friel as Executive Chairman

Independent Research Confirms >$10 Billion Market Opportunity for POLB 001 as A Preventative Therapy for Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS)

Poolbeg Pharma plc Further Data Confirms Polb 001'S Potential in Cancer Immunotherapy-Induced Cytokine Release Syndrome

High number of new and inexperienced directors

Poolbeg Pharma plc Announces Positive Outputs from Lab-Based Analysis of RSV Drug Candidates Identified Using AI RSV Drug Candidates with the High Probability of Successful Successful Successfully

Poolbeg Pharma plc Announces Key Insights from Its Poster Presentation at ASH POLB 001

Poolbeg Pharma plc Announces Directorate Changes

Poolbeg Pharma plc Announces Executive Appointments

Poolbeg Pharma plc Announces Scientific Advisory Board Endorses Influenza Drug Targets Identified in Ai Drug Discovery Programme

Poolbeg Pharma PLC Announces Favourable Conclusion of Patent Opposition

Poolbeg Pharma Receives Notice of Allowance from the Japanese Patent Office in Relation to its Immunomodulator I Patent Application

Poolbeg Pharma plc Announces Immunomodulator I Patent Opposition Withdrawal

Poolbeg Pharma plc Announces Significant Breakthrough in Its World First Influenza Artificial Intelligence Programme with Cytoreason

Less than half of directors are independent

Poolbeg Pharma PLC Announces Board Changes

Poolbeg Pharma plc Announces Strategic Expansion of Polb 001 into Oncology

Poolbeg Pharma PLC Announces Positive Initial Data Analysis in POLB 001 Trial

Poolbeg Pharma Identifies Novel RSV Drug Candidates

Poolbeg Pharma plc Announces POLB 001 LPS Human Challenge Clinical Trial Successfully Completed

Poolbeg Pharma Announces Completion of Influenza AI Model Build

Poolbeg Pharma PLC to Report First Half, 2022 Results on Sep 06, 2022

Poolbeg Pharma plc Receives Ethics and Competent Authority Approval to Commence Its Lipopolysaccharide (Lps) Human Challenge Clinical Trial for Polb 00

Poolbeg Pharma plc Provides Project Update for AI Model of RSV Data

Poolbeg Pharma PLC Provides Update on POLB 001 Clinical Development

No independent directors

Poolbeg Pharma plc Provides an Update on the Strengthening of Its Intellectual Property for Its Asset POLB 002

Poolbeg Pharma PLC to Report Q4, 2021 Results on Mar 03, 2022

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd